The complex world of polysaccharides edited by Desiree Nedra Karunaratne

 

The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14  627 

To improve the immunogenicity of oligosaccharide-protein conjugates co-delivery of 

adjuvants are required. As an alternative to the addition of adjuvants, studies should be 

initiated to direct oligosaccharide-protein conjugates to dendritic cells by incorporation of 

specific ligands. Targeting to and activation of dendritic cells by TLR5 is a possibility to be 

explored. 

Author details 

Dodi Safari

*

 

Eijkman Institute for Molecular Biology, Jakarta, Indonesia 

Ger Rijkers 

Department of Sciences, Roosevelt Academy, Middelburg and Department of Medical Microbiology 

and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands  

Harm Snippe 

Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands 

Acknowledgement 

This review is a part of the PhD thesis of Dodi Safari with the title: Development of new 

synthetic oligosaccharide vaccines: the immunogenicity of oligosaccharide- CRM

197 

neoconjugates and oligosaccharide/peptide hybrid gold nanoparticles based on the capsular 

polysaccharide structure of Streptococcus pneumoniae type. 14. Utrecht University. 2010. This 

work was supported by a grant from the European Commission under Contract No: MRTN-

CT-2004-005645. 

7. References 

[1]  Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical 

compounds. J.Exp.Med. 1935;61:643-56. 

[2]  Mitchison NA; Rajewsky K; Taylor RB. Sterzl J and Riha I, editors.Prague symposium 

on developmental aspects of antibody formation and structure. Praha: Academia 

Publishing House; 1970. 

[3]  Goebel WF. Studies on antibacterial immunity induced by artificial antigens. I. 

Immunity to experimental pneumococcal infection with an antigen containing 

cellobiuronic acid. J.Exp.Med. 1939;69:353-64. 

[4]  Goebel WF. Studies on antibacterial immunity induced by artificial antigens. II. 

Immunity to experimental pneumococcal infection with antigens containing saccharides 

of synthetic origin. J.Exp.Med. 1940;72:33-48. 

[5]  Campbell JH, Pappenheimer AM. Quantitative studies of the specificity of anti-

pneumococcal polysaccharide antibodies, type III and VIII. I. Isolation of 

                                                                 

*

 Corresponding Author 

---

 

The Complex World of Polysaccharides 

628 

oligosaccharides from acid and from enzymatic hydrolysates. Immunochemistry 

1966;3:195-212. 

[6]  Mage RG, Kabat EA. Immunochemical studies on dextrans: III. The specificities of 

rabbit antidextrans. Further findings on antidextrans with 1,2- and 1,6-specificities. 

J.Immunol. 1963;(91):633-40. 

[7]  Kabat EA; Mayer MM. Experimental immunochemistry. IL, USA: Springfield; 1948. 

[8]  Snippe H, van Dam JEG, van Houte AJ, Willers JMN, Kamerling JP, Vliegenthart JFG. 

Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3. Infect.Immun. 

1983;42(2):842-4. 

[9]  Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez A, Baly A, 

Harrera L, Izquierdo M, Villar A, Valdes Y, Cosme K, Deler ML, Montane M, Gracia E, 

Ramos A, Aguilar A, Medina E, Torano G, Sosa I, Hernandez I, Martinez R, Muzachio 

A, Carmenates A, Costa L, Cardoso F, Campa C, Diaz V, Roy R. A synthetic conjugate 

polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;305:522-5. 

[10] Safari D, Maradi M, Chiodo F, Dekker HA, Shan Y, Adamo R, Oscarson S, Rijkers GT, 

Lahmann M, Kamerling JP, Penades S, Snippe H. Gold nanoparticles as carriers for a 

synthetic  Streptococcus pneumoniae type 14 conjugate vaccine. Nanomedicine 

2012;doi:10.2217/NNM.11.151 

[11] Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in 

children. Lancet 2005;365(9465):1147-52. 

[12] 

World Health Organization. Pneumococcal conjugate vaccine for childhood 

immunization--WHO position paper. Wkly.Epidemiol.Rec. 2007;82(12):93-104. 

[13] Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae 

virulence factors in host respiratory colonization and disease. Nat.Rev.Microbiol 

2008;6(4):288-301. 

[14] de Velasco EA, Verheul AF, Verhoef J, Snippe H. Streptococcus pneumoniae: virulence 

factors, pathogenesis, and vaccines. Microbiol.Rev. 1995;59(4):591-603. 

[15] van der PT, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal 

pneumonia. Lancet 2009;374(9700):1543-56. 

[16] Kamerling JP. Tomasz A, editors. Streptococcus pneumoniae, molecular biology & 

mechanisms of disease. New York: Mary Ann Liebert; 1999;Pneumococcal 

polysaccharides: A chemical view. p. 81-114. 

[17] Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of 

a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J 

Clin.Microbiol 2007;45(4):1225-33. 

[18] Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identification of natural 

pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological 

characterization. Microbiology 2010;156:555-60. 

[19] Oftadeh S, Satzke C, Gilbert GL. Identification of the newly described Streptococcus 

pneumoniae serotype 6D using Quellung reaction and PCR. J Clin.Microbiol 2010; 

[20] Calix JJ, Nahm MH. A new pneumococcal serotype, 11E, has a variably inactivated wcjE 

gene. J Infect.Dis. 2010;202(1):29-38. 

---